LE
Lexaria Bioscience Corp.
LEXXW · NASDAQ
$0.01 +31.87% (+$0.00)
Market Cap $201.2K
P/E Ratio -
Div. Yield -
ROE 149.35%
Bulios Fair Price
$0
100.0% downside
Current Price
$0.012
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LEXXW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 0.33x
P/B 0.04x
P/E N/A
Growth
13 /100
Declining Rev. growth 10.43%
Book val. growth 6.43%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 99.56%
Net margin 1,849.39%
FCF margin 1,586.10%
Quality
1 /100
Poor ROIC 215.76%
ROE 149.35%
Asset turnover 0.09x
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 3.90x
Net debt/EBITDA 0.40x
Stability
28 /100
Unstable Beta 0.37x
Rev. volatility 100.38%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LEXXW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard C. Christopher
Employees
7
Headquarters
Kelowna